Vezicle™ Liposomal Vitamin K2 MK-7 Powder, NLT 1,500 µg/g
Liposomal Vitamin K2 MK-7 Powder is a single-active, immediate-release ingredient developed for low-dose uniformity and dispersion in professional supplement formulations.
For business buyers. Technical documentation is available on request.
How the sample programme worksProduct information
Vezicle™ Liposomal Vitamin K2 MK-7 Powder, NLT 1,500 µg/g — technical specification and documentation
Review the key specifications at a glance, then expand only the sections you need.
Liposomal Vitamin K2 MK-7 Powder is a single-active, immediate-release ingredient developed for low-dose uniformity and dispersion in professional supplement formulations.
It provides NLT 1,500 µg/g vitamin K2 as menaquinone-7 in a characterised phospholipid vesicle powder for premixes, capsules, tablets and powder blends.
- Low-dose formulation: designed to support uniform distribution, dispersion and dry-powder handling.
- Characterised structure: liposomal terminology is supported by phospholipid vesicle characterisation.
- Evidence-led supply: manufactured and released against an approved specification, with batch-specific results reported by Certificate of Analysis.
Qualified / in stock · 50 g evaluation sample at €40 ex VAT · Typical lead time 3–5 business days
The evaluation-sample fee is credited against the first commercial order placed within 12 months. The TDS, finished-product specification, batch CoA, SDS and liposomal characterisation data are available on request.
No absorption or human-bioavailability claim is made.
What is the technical summary?
| Product code | NG-LIP-001 |
|---|---|
| Active ingredient | Vitamin K2 as menaquinone-7 |
| Assay | NLT 1,500 µg/g vitamin K2 as MK-7 |
| Technology | Liposomal delivery |
| Delivery system | Characterised phospholipid vesicle system |
| Product format | Single-active dry powder |
| Release behaviour | Immediate / non-modified |
| Product status | Qualified / in stock |
| Best-fit applications | Premixes, capsules, tablets and powder blends |
How can B2B buyers order and request documentation?
| Evaluation sample | 50 g — €40 ex VAT |
|---|---|
| Sample-fee credit | Credited against the first commercial order within 12 months |
| Stocked MOQ | 1 kg |
| Standard packs | 1 kg and 5 kg |
| Bulk pack | 25 kg by quotation |
| Typical lead time | 3–5 business days when in stock |
| Documentation | Current technical and quality package available on request |
| Custom strength | Subject to technical and commercial feasibility |
| Custom packaging | Available by quotation |
Which formulation problems does this ingredient address?
Why is vitamin K2 MK-7 difficult to formulate at low dose?
Vitamin K2 MK-7 is incorporated at microgram-level doses, making uniform distribution across larger powder blends an important formulation consideration. The ingredient may also be affected by light, oxidation, alkaline conditions and direct interaction with certain minerals or other formulation components.
How does the NexaGens format address the formulation challenge?
This liposomal Vitamin K2 powder uses a characterised phospholipid vesicle system in a dry, single-active format. It is designed to support low-dose distribution, dispersion and protection from formulation stress while retaining immediate, non-modified release.
The ingredient can be used as an independent formulation module and assessed alongside other ingredients according to the requirements of the finished product.
What is the full technical specification?
The key public specification is NLT 1,500 µg/g vitamin K2 as MK-7 with Immediate / non-modified release behaviour; batch acceptance follows the approved product-specific specification and analytical method.
The product is manufactured and released against an approved finished-product specification. Applicable controls cover:
- Identity and vitamin K2 MK-7 assay
- MK-7 profile
- Phospholipid vesicle characterisation
- Particle-size characteristics
- Bulk and tapped density
- Moisture or loss on drying
- Water activity
- Dispersibility and powder handling
- Appearance, colour and odour
- Microbiological limits
- Heavy metals and applicable contaminants
- Residual-solvent compliance
- Storage conditions and shelf life
Detailed numerical limits are provided in the current finished-product specification. Batch-specific results are reported in the Certificate of Analysis.
What is the public composition?
The public composition identifies Vitamin K2 MK-7 with a Food-grade phospholipid delivery system and powder carrier; exact proprietary excipient ratios and supplier details remain controlled.
| Component | Function | Public information |
|---|---|---|
| Vitamin K2 MK-7 | Active ingredient | Menaquinone-7 from a product-specific qualified source; NLT 1,500 µg/g |
| Food-grade phospholipid system | Vesicle-forming delivery system | Controlled product-specific phospholipid composition |
| Food-grade carrier and protective matrix | Powder formation and physical stability | Product-specific carrier system, q.s. to 100% |
Exact proprietary quantities are maintained in the controlled product dossier. Country of origin is stated in the current Country of Origin Statement.
How is performance verified?
Performance is verified using approved product-specific methods and the controlled evidence listed below.
| Verification area | Evidence |
|---|---|
| Identity and assay | Approved finished-product specification and batch Certificate of Analysis |
| Liposomal structure | Characterisation of the phospholipid vesicle system |
| Stability and shelf life | Current product-specific stability documentation |
| Microbiological quality | Finished-product microbiological specification |
| Heavy metals and contaminants | Approved finished-product specification |
The liposomal terminology applies to the characterised supplied ingredient. Performance in a finished product must be confirmed in the customer’s formulation and manufacturing process.
How should formulators process and evaluate it?
- Pre-disperse the ingredient where required by the dosage form or manufacturing process.
- Minimise prolonged exposure to heat, moisture and direct light.
- Avoid strong oxidants and extreme-pH processing conditions.
- Assess compatibility with minerals, surfactants and other formulation components.
- Verify low-dose uniformity across the final blend.
- Confirm stability and performance in the finished product.
- Follow the product-specific reconstitution and dispersion protocol.
Which technical and quality documents are available?
Core technical documents
- Technical Data Sheet
- Finished Product Specification
- Batch Certificate of Analysis
- Safety Data Sheet
- Liposomal Characterisation Data
- Stability Documentation
- Composition and Ingredient Information
- Storage and Handling Information
Quality and compliance documents
- Allergen Statement
- GMO Statement
- Irradiation Statement
- BSE/TSE Statement
- Microbiological Specification
- Heavy Metals Specification
- Country of Origin Statement
- Manufacturing or Quality Certificate
Full controlled composition or characterisation details may require an NDA. Tell NexaGens which documents you require and whether they are needed for evaluation, formulation, supplier qualification or regulatory review.
What must buyers confirm for regulatory and intended use?
Regulatory suitability depends on the intended use, dose and target market; the customer must confirm finished-product compliance.
| Target market | European Union / EEA |
|---|---|
| Intended use | Food supplements and professional formulation use |
| Label declaration | Vitamin K2 MK-7 |
| Ingredient legal status | Product-specific assessment available; intended use and national requirements must be confirmed by the customer |
| Novel-food review | Product-specific assessment available |
| Carrier compliance | Reviewed for the intended product scope |
| Allergen and GMO status | Confirm against the current product-specific declarations |
| Vegan, vegetarian, halal and kosher status | Confirm against the applicable current statement or certificate |
| Use level | Determined by the customer’s formulation, applicable legislation and technical assessment |
How should it be stored and handled?
Store tightly closed in original packaging in a cool, dry place, protected from heat, moisture and direct light. Free-flowing powder with product-specific colour and odour; see TDS and batch CoA.
Reseal promptly after opening and follow the storage conditions stated in the current Technical Data Sheet and stability documentation.
Frequently asked questions
Is this a characterised liposomal ingredient?
Yes. NexaGens uses liposomal terminology because phospholipid vesicle structure has been characterised for the supplied ingredient. Supporting characterisation data are available on request.
Is it immediate or modified release?
It is an immediate, non-modified-release powder. No sustained-release or enteric-release claim is made.
Which applications are suitable?
Potential applications include premixes, capsules, tablets and powder blends. Final suitability depends on the complete formulation and manufacturing process.
Can it be combined with other ingredients?
It may be combined with other formulation components or independent NexaGens modules. Compatibility, low-dose uniformity and stability must be confirmed in the finished product.
What documentation is available?
The available package includes the TDS, finished-product specification, batch CoA, SDS, liposomal characterisation data and applicable quality, regulatory and stability documents.
Can I order an evaluation sample?
Yes. A 50 g evaluation sample is available for €40 ex VAT. The fee is credited against the first commercial order placed within 12 months.
What is the commercial MOQ?
The stocked commercial MOQ is 1 kg. Standard packs are 1 kg and 5 kg, while 25 kg quantities are supplied by quotation.
What does NexaGens not claim?
For professional B2B food, food-supplement and formulation use only. Not intended for direct consumer use.
No medicinal, disease-treatment, absorption or human-bioavailability claim is made. Performance depends on the complete formulation and processing conditions. The customer remains responsible for confirming dosage, permitted use, product classification, label declarations, claims and market compliance.
Need the controlled document package?
Request the current technical, quality, stability and compliance documents for this ingredient.
Related formulation guides
Review the formulation challenges most relevant to this ingredient before requesting evaluation material or documentation.
View all liposomal ingredients